Skip to navigationSkip to content

Does the cannabis industry have a monopoly problem?

a gloved hand holds cannabis flowers in a close-up photo
Reuters/Amir Cohen
Cannabis companies are getting a closer look from the feds.
  • Jenni Avins
By Jenni Avins

senior lifestyle correspondent

Published Last updated on

On June 24, US Department of Justice whistleblower John Elias testified that attorney general William Barr ordered investigations of 10 cannabis mergers in the 2019 fiscal year based on personal dislike of the industry. If that sounds like a lot, he said, it is. According to Elias’s testimony (pdf), those reviews accounted for 29% of the antitrust division’s full merger investigations during that period.

“These mergers involve companies with low market shares in a fragmented industry; they do not meet established criteria for antitrust investigations,” wrote Elias, whose job description includes prosecuting price-fixing schemes in the pharmaceutical industry. Elias claimed that his team prepared a memo for Barr explaining as much, but that Barr rejected the recommendation. “The rationale for doing so centered not on an antitrust analysis, but because he did not like the nature of their underlying business.”

Now, more than 30 members of Congress are backing a resolution to investigate and impeach Barr for abusing his power and misusing resources (pdf) based on Elias’s testimony.

Enrich your perspective. Embolden your work. Become a Quartz member.

Your membership supports a team of global Quartz journalists reporting on the forces shaping our world. We make sense of accelerating change and help you get ahead of it with business news for the next era, not just the next hour. Subscribe to Quartz today.

Membership includes:

Quartz Japanへの登録をご希望の方はこちらから。